Navigation Links
Catalyst Pharmaceutical Partners Reports First Quarter 2009 Financial Results
Date:5/14/2009

by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. For more information about the Company, go to www.catalystpharma.com.

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including our ability to successfully complete the clinical trials required for us to file a new drug application for CPP-109, our ability to complete such trials on a timely basis within the budgets we establish for such trials, our ability to protect our intellectual property and those other factors described in the Company's Annual Report on Form 10-K for 2008 and the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 that the Company has filed with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect the Company. Copies of the Company's filings with the SEC are available from the SEC, may be found on the Company's website or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.


                    CATALYST PHARMACEUTICAL PARTNERS, INC.
                        (a development stage company)

                 CONDENSED STATEMENTS OF OPERATIONS (unaudited)

                                             For the Three Months Ended
                                                      March 31,
                                 
'/>"/>
SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results
4. Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
5. CATalyst Summit Declared a Success: Its All About the Cat!
6. Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the Investment in Innovation (In3) West Conference on February 29, 2008 in Las Vegas, NV
7. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
8. Case in Point: Patient Control of Data Critical Catalyst for Online Health Care Revolution
9. Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index
10. Congress Approves ePrescribing Initiative in Medicare Reform Bill: Critical Catalyst in Driving a New Generation of Prescribing
11. CATalyst Council Forms to Address Feline Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... 25, 2015 The Hon. Ellen Tauscher, ... issues the following statement following the deadly earthquake in ... Nepal, resulting in the deaths of more than 1,000 ... felt across Nepal, Bangladesh, India and other parts of ... condolences to the people of Nepal and the families ...
(Date:4/25/2015)... (PRWEB) April 25, 2015 By definition, a ... data for the enterprise relying on their judgement and expertise ... But according to an article published in National ... times actually be doing a disservice to their responsibilities by ... dotted and t’s are crossed when it comes to company ...
(Date:4/25/2015)... 25, 2015 Parker and Sons projects growth ... has spiked in Arizona alongside the growing economy. As a ... employees for April to help account for the rising need ... in April is something we are enthusiastic about. It means ... Kelly, president at Parker and Sons. , Indeed, Parker and ...
(Date:4/25/2015)... For thirteen years, the Twin Cities DI Day has been ... nation! This year, on May 5th, 2015, Secura Consultants is ... Day on the road by supporting the first ever National ... CLTC, Chief Executive Officer at Secura Consultants and co-creator of ... stating, "The first Twin Cities DI Day was a hugely ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 As the ... and the unique sacrifices of these young men and ... Service members, Veterans and their Families” presents a special ... is designed to gain a better understanding of the ... and wellness. For those – civilian and military – ...
Breaking Medicine News(10 mins):Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Parker and Sons Plans to Expand in 2015 2Health News:Secura Consultants Takes DI Day On The Road 2Health News:Coalition Presents Resiliency Training to Raise Awareness during Month of the Military Child (#MOTMC2015) 2
... ... MRSA. Jan-Pro, Global Leader in Commercial Cleaning, Once Again Leads the Way in Infection ... Solution in the control of infectious microorganisms - EnviroShield Disinfectant Technology , ... (PRWEB) June 1, 2010 -- ...
... , ... of Midbrook, Inc.) is proud to announce they have recently been awarded an agreement with ... the nation’s largest healthcare group purchasing organizations and serves 2,300 hospitals and more than 66,000 ... ...
... GIA announces the ... Proteins market is anticipated to reach 472.3 million pounds by 2015, driven largely by functional ... processing and investments in R&D are other major driving forces for the growth of the ... San ...
... ... purchase used equipment from CosmeticLaserWorld.com can now rely on a brand new buy back ... (PRWEB) ... and doctors, recently unveiled yet another reason savvy spas should purchase equipment from the ...
... resulting from an inherited defect that prevents the proper metabolism ... milk. Exposure of affected people to galactose, can damage most ... to study the disease is limited by a lack of ... and flies may provide scientists with useful clues. The ...
... The American College of Radiology,s (ACR) Task Force on ... Organizations has proposed several steps that can help improve ... they service, according to an article in the June ... of Radiology ( www.jacr.org ). "The ...
Cached Medicine News:Health News:JAN-PRO Launches Exclusive “EnviroShield™” Disinfecting System - Kills Harmful Bacteria, Including MRSA 2Health News:JAN-PRO Launches Exclusive “EnviroShield™” Disinfecting System - Kills Harmful Bacteria, Including MRSA 3Health News:Midbrook Medical Announces Agreement with Premier Partners L.P. 2Health News:Midbrook Medical Announces Agreement with Premier Partners L.P. 3Health News:US Whey Proteins Market to Reach 472.3 Million Pounds by 2015, According to New Report by Global Industry Analysts, Inc. 2Health News:US Whey Proteins Market to Reach 472.3 Million Pounds by 2015, According to New Report by Global Industry Analysts, Inc. 3Health News:CosmeticLaserWorld.com Gives Buyers Peace of Mind Through Industry-Leading Investment Protection Plan 2Health News:Flies offer insight into human metabolic disease 2Health News:ACR task force makes recommendations for improving relationships between radiologists and hospitals 2
(Date:4/24/2015)... EAST HANOVER, N.J. , April 24, 2015  Novartis ... diversity for the second year in a row on the ... the results of its 2015 Top 50 Companies for Diversity ... New York, NY . NPC also ranked second on ... on the Top 10 Companies for Employee Resource Groups list. ...
(Date:4/24/2015)... , April 24, 2015 /CNW/ - T-Bird Pharma ... focused on developing premium quality medical marijuana products and ... Marihuana for Medical Purposes Regulations ( Canada ... with certain of its shareholders, has closed the transaction ... ("Medna").  Medna has acquired (the "Escrow Transfer") a total ...
(Date:4/23/2015)... Ill. , April 24, 2015  AbbVie (NYSE: ... and Drug Administration (FDA) has accepted its New Drug ... all-oral, interferon-free, two direct-acting antiviral treatment of ombitasvir, paritaprevir, ... the treatment of adults with chronic genotype 4 (GT4) ... is the first all-oral, interferon-free therapy being evaluated by ...
Breaking Medicine Technology:Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 2Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 3Novartis Pharmaceuticals Corporation is first company to receive number one ranking two years in a row on DiversityInc Top 50 Companies for Diversity list 4T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
... LAKES, N.J., Jan. 11 BD (Becton, Dickinson and Company) (NYSE: ... live webcast of its first fiscal quarter 2010 earnings conference call ... will issue a press release detailing the quarter,s earnings earlier that ... slides, will be accessible through BD,s website at www.bd.com/investors ...
... , WASHINGTON, Jan. ... that Major League Baseball star Aaron Boone is featured in ... public affairs television program that tells the compelling and inspirational stories of ... television stations nationwide. It is sponsored by the Pharmaceutical Research and ...
Cached Medicine Technology:BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call 2Major League Baseball Star Aaron Boone on 'Sharing Miracles' 2Major League Baseball Star Aaron Boone on 'Sharing Miracles' 3
... and Nitrogen Blow-Down Evaporators. For over ten years TurboVap concentration technology has received enormous acclaim with over ... ... ... ...
Plastic Tray Type Vacuum Manifold...
QIAvac 6S provides all manifold components for processing QIAGEN 8-well strips....
For connecting the QIAvac 24 Plus and Vacuum Pump;...
Medicine Products: